2017
DOI: 10.1371/journal.pone.0170269
|View full text |Cite
|
Sign up to set email alerts
|

Protective Roles for RGS2 in a Mouse Model of House Dust Mite-Induced Airway Inflammation

Abstract: The GTPase-accelerating protein, regulator of G-protein signalling 2 (RGS2) reduces signalling from G-protein-coupled receptors (GPCRs) that signal via Gαq. In humans, RGS2 expression is up-regulated by inhaled corticosteroids (ICSs) and long-acting β2-adrenoceptor agonists (LABAs) such that synergy is produced in combination. This may contribute to the superior clinical efficacy of ICS/LABA therapy in asthma relative to ICS alone. In a murine model of house dust mite (HDM)-induced airways inflammation, three … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
30
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
4
2
1

Relationship

1
6

Authors

Journals

citations
Cited by 26 publications
(31 citation statements)
references
References 71 publications
1
30
0
Order By: Relevance
“…Likewise, other GO terms indicate positive effects on proliferation and negative effects on apoptosis. Of the four genes associated with GO terms for signaling, one of these, RGS2, a positive regulator of GTPase activity, promotes inactivation of signaling from many pro-asthma G-protein coupled receptors (GPCRs) and is implicated in the therapeutic benefits of glucocorticoids in the airways [33][34][35][36]. ERRFI1 and IRS2 relate to tyrosine kinase-linked and insulin signaling, while the fourth signaling gene, RGCC, is a regulator of the cell cycle and is therefore also likely to operate alongside other genes involved in proliferation and/or apoptosis.…”
Section: Gene Expression Changes In Response To Different Glucocorticmentioning
confidence: 99%
“…Likewise, other GO terms indicate positive effects on proliferation and negative effects on apoptosis. Of the four genes associated with GO terms for signaling, one of these, RGS2, a positive regulator of GTPase activity, promotes inactivation of signaling from many pro-asthma G-protein coupled receptors (GPCRs) and is implicated in the therapeutic benefits of glucocorticoids in the airways [33][34][35][36]. ERRFI1 and IRS2 relate to tyrosine kinase-linked and insulin signaling, while the fourth signaling gene, RGCC, is a regulator of the cell cycle and is therefore also likely to operate alongside other genes involved in proliferation and/or apoptosis.…”
Section: Gene Expression Changes In Response To Different Glucocorticmentioning
confidence: 99%
“…In prior studies, we found no differences in the total or differential BAL fluid cell counts between naïve, non-inflamed, wild type and Rgs2 − / − animals [ 26 , 28 ]. In each case, wild type or Rgs2 − / − animals, the total cell counts were essentially identical and consisted of macrophage.…”
Section: Resultsmentioning
confidence: 74%
“…Breeding from heterozygous Rgs2 − / + pairs to produce wild type and Rgs2 − / − knockout littermates allowed lung function to be compared between wild type and Rgs2 − / − animals. In prior studies [ 26 , 28 ], we found that control animals, without any pro-inflammatory insult, showed AHR due to Rgs2 loss. In the current study, N = 6 wild type and N = 3 Rgs2 − / − animals were subjected to PBS exposure and lung function was examined.…”
Section: Resultsmentioning
confidence: 89%
See 1 more Smart Citation
“…This hypothesis was later confirmed by the same authors who used knockout animals to demonstrate the bronchoprotective role of RGS2 in a murine model of house dust mite-induced allergic inflammation. Interestingly, the authors also found that the presence of RGS2 was required to suppress allergen-associated pulmonary inflammation including production of different chemokines such as CCL3, CCL11, CXCL9 and CXCL10 (George et al, 2017). Combined therapy also inhibits features of ASM remodelling where low doses of fluticasone synergized with fenoterol to suppress PDGFinduced proliferation and hypocontractility in bovine tracheal smooth muscle cells (Dekkers et al, 2012).…”
Section: -Therapeutic Actions Of β2-adrenoceptor Agonists In Asthmamentioning
confidence: 98%